Merck KGaA And Novartis Back In Horse Race For First Oral MS Drug To Market
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA granted the reworked cladribine NDA submitted in June by U.S. affiliate EMD Serono a six-month priority review, with approval possible in the fourth quarter, while action is anticipated on Gilenia in September.